1-(2-氯苯基)-2,2-二甲基-丙-1-醇 | 6642-36-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-氯苯基)-2,2-二甲基-丙-1-醇
• 英文名称: α-tert-butyl-2-chlorobenzyl alcohol
• 英文别名: 1-(2-chlorophenyl)-2,2-dimethylpropan-1-ol；α-tert-butyl-2-bromobenzyl alcohol；(±)-1-(2-chlorophenyl)-2,2-dimethyl-1-propanol；(RS)-1-(2-chlorophenyl)-3,3-dimethyl-1-butanol；2,2-dimethyl-1-(2-chlorophenyl)-1-propanol
• CAS: 6642-36-0
• 化学式: C₁₁H₁₅ClO
• 分子量: 198.692
• InChiKey: SLMVMIYHMKFKFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-氯苯基)-2,2-二甲基-丙-1-醇 在 硫酸氢铵 、 六甲基二硅氮烷 作用下， 以 neat (no solvent) 为溶剂， 反应 3.67h， 生成
  参考文献：
  名称：

  N-羟基胞苷的修饰产生了一种新型先导化合物，具有抗委内瑞拉马脑炎病毒的活性

  摘要：

  能够干扰核酸合成的核苷和核碱基类似物在对抗传染病方面发挥了重要作用。然而，这些药物中的许多都与重要且可能致命的脱靶细胞内效应有关，从而限制了它们的使用。基于之前发现的碱基修饰的 2'-脱氧尿苷，与抗代谢化疗药物相比，它表现出高抗癌活性，同时对快速分裂的正常人类细胞表现出较低的毒性，我们假设N 4 -羟基胞苷 (NHC) 分子的类似修饰将提供副作用减少的新型抗病毒化合物。这一推测是由于与天然胞苷的显着结构差异导致宿主细胞酶的识别能力较低。在针对 VEEV 合成和筛选的 42 种抗代谢药物中，鉴定出一种有效化合物。该修饰部分的结构特征与之前报道的抗癌先导2′-脱氧尿苷衍生物的结构特征相似，为进一步进行针对先导改进的构效关系（SAR）研究提供了机会，并深入了解作用机制，这可以导致识别针对广谱 RNA 病毒感染的候选药物。

  DOI：

  10.1016/j.bmcl.2023.129432
• 作为产物：
  描述：

  o-chlorobenzaldehyde 、 叔丁基氯化镁 以 四氢呋喃 为溶剂， 以92%的产率得到1-(2-氯苯基)-2,2-二甲基-丙-1-醇
  参考文献：
  名称：

  Base-modified thymidines capable of terminating DNA synthesis are novel bioactive compounds with activity in cancer cells

  摘要：

  Current FDA-approved chemotherapeutic antimetabolites elicit severe side effects that warrant their improvement; therefore, we designed compounds with mechanisms of action focusing on inhibiting DNA replication rather than targeting multiple pathways. We previously discovered that 5-(alpha-substituted-2-nitrobenzyloxy)methyluridine-5 '-triphosphates were exquisite DNA synthesis terminators; therefore, we synthesized a library of 35 thymidine analogs and evaluated their activity using an MTT cell viability assay of MCF7 breast cancer cells chosen for their vulnerability to these nucleoside derivatives. Compound 3a, having an alpha-tert-butyl-2-nitro-4-(phenyl)alkynylbenzyloxy group, showed an IC50 of 9 +/- 1 mu M. The compound is more selective for cancer cells than for fibroblast cells compared with 5-fluorouracil. Treatment of MCF7 cells with 3a elicits the DNA damage response as indicated by phosphorylation of gamma-H2A. A primer extension assay of the 5 '-triphosphate of 3a revealed that 3aTP is more likely to inhibit DNA polymerase than to lead to termination events upon incorporation into the DNA replication fork. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.01.057

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Lopez Omar D.

  公开号：US20110294819A1

  公开（公告）日：2011-12-01

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物，包括这些化合物的组合物以及抑制NS5A蛋白功能的方法。
• NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS
  申请人：UNIVERSITY OF CINCINNATI

  公开号：US20160101188A1

  公开（公告）日：2016-04-14

  Compositions and methods for treating cancer in a subject are described herein. The composition includes modified nucleobases and nucleosides that are converted in the cell to nucleotides that are incorporated into growing DNA and result in termination of DNA elongation. The nucleobases and nucleotides are incorporated with a drug delivery system (DDS). The DDS includes β-cyclodextrin. The nucleobases and nucleotides are conjugated to the β-cyclodextrin by an acid labile linker that releases the nucleobases and nucleotides in the acidic environment of cancer cells. The DDS may also include a targeting ligand that targets the DDS/nucleobase or nucleotide conjugate to cancer cells. The DDS/nucleobase or nucleotide conjugate may self form into nanoparticles and may be administered to a subject with cancer in an amount effective to treat said cancer.

  本文描述了用于治疗患者癌症的组合物和方法。该组合物包括经过修饰的核碱基和核苷，这些核碱基和核苷在细胞中转化为核苷酸，并被合并到正在生长的DNA中，导致DNA延伸终止。这些核碱基和核苷与药物输送系统（DDS）一起使用。DDS包括β-环糊精。核碱基和核苷通过酸敏链连接到β-环糊精上，该链在癌细胞的酸性环境中释放核碱基和核苷。DDS还可以包括靶向配体，将DDS/核碱基或核苷共轭物靶向癌细胞。DDS/核碱基或核苷共轭物可以自行形成纳米粒子，并可以以有效治疗癌症的剂量给患者服用。
• Bu₄N⁺ Alkoxide-Initiated/Autocatalytic Addition Reactions with Organotrimethylsilanes
  作者：Manas Das、Donal F. O’Shea

  DOI：10.1021/jo5007637

  日期：2014.6.20

  The use of Me3SiO(-)/Bu4N(+) as a general activator of organotrimethylsilanes for addition reactions has been established. The broad scope of the method offers trimethylsilanes (including acetate, allyl, propargyl, benzyl, dithiane, heteroaryl, and aryl derivatives) as bench-stable organometallics that can be readily utilized as carbanion equivalents for synthesis. Reactions are achieved at rt without the requirement of specialized precautions that are commonplace for other organometallics.
• [EN] NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS<br/>[FR] NOUVEAUX AGENTS CHIMIOTHÉRAPEUTIQUES ANTICANCÉREUX DÉLIVRÉS PAR NANO-PORTEUR
  申请人：UNIV CINCINNATI

  公开号：WO2014194250A3

  公开（公告）日：2015-04-09
• US8362020B2
  申请人：——

  公开号：US8362020B2

  公开（公告）日：2013-01-29